Model appropriateness and population pharmacokinetic modeling.

Area of Science:

• Pharmacokinetics and Drug Development
• Mathematical Modeling in Pharmacology
• Computational Biology

Background:

• Population pharmacokinetic (PPK) models are crucial for understanding drug behavior in diverse patient groups.
• Determining the appropriateness of these models is essential for their reliable application in clinical practice.
• Existing frameworks for assessing PPK model appropriateness require refinement to encompass both descriptive and predictive uses.

Purpose of the Study:

• To define model appropriateness and identify its constituent elements for PPK models.
• To establish a framework for determining model appropriateness tailored to the specific problem and intended use.
• To illustrate the application of this framework using a case study for 5-fluorocytosine dosing.

Main Methods:

• Defined model appropriateness based on problem statement and intended use.
• Differentiated elements of appropriateness based on model type (descriptive vs. predictive).
• Employed percentile bootstrapping for model evaluation and validation; utilized NONMEM and Pharsight Trial Designer for simulation.

Main Results:

• Model appropriateness hinges on clearly defining the problem and intended use.
• Descriptive PPK models require evaluation of fit, reliability, and stability; predictive models additionally need validation.
• The 5-fluorocytosine PPK model demonstrated the utility of the appropriateness framework, favoring the UCSD dosing method.

Conclusions:

• Applying principles of model appropriateness enhances confidence in PPK model application for intended uses.
• A systematic approach to model appropriateness ensures PPK models effectively address specific research or clinical questions.
• This framework facilitates the comparison of competing dosing strategies, optimizing therapeutic outcomes.